PrecisePRP™ Canine
Canine leucoreduced allogeneic pooled freeze-dried platelet-rich plasma
VetStem, Inc.

PrecisePRP™ Canine
Canine leucoreduced allogeneic pooled freeze-dried platelet-rich plasma

For intra-articular injection in dogs only

4.0 x 10^9 canine platelets / vial, lyophilized
< 1500 white blood cells / µL

Single patient use vial for rehydration to 8 mL with sterile water

A freeze-dried species-specific source of concentrated platelets in plasma

CAUTION:

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

PrecisePRP™ Canine is a leucoreduced allogeneic, pooled, freeze-dried platelet-rich plasma product from up to 36 canine donors. The biological source material for this product is in-date, apheresis-derived canine platelet concentrates leucoreduced to less than 1500 white blood cells per µL and apheresis-derived or whole blood-derived frozen plasma. Plasma antibody to DEA 1.1, 3, 4, 5, and 7 have been tested in all donors. Donors are selected and evaluated for infectious disease in accordance with FDA CVM Guidance #254. Supplied in a 50 mL glass vial, this product is a sterile, nonpyrogenic white-to-tan powder. Once rehydrated with 8 mL of sterile water for injection, this product is a light yellow translucent fluid with 4.0 x 10^9 platelets per vial and less than 1500 white blood cells per µL.

INDICATION:

PrecisePRP™ Canine is intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration.

DOSAGE AND ADMINISTRATION:

PrecisePRP™ Canine is for intra-articular administration only. One vial provides 8 mL of allogeneic pooled platelet-rich plasma with a total of approximately 4 x 10^9 canine platelets per vial and less than 1500 white blood cells per µL. Do not mix this product with other products or solutions. Use according to **Table 1** and adjust the dose based on the size of the dog and the joint being treated.

Rehydration Instructions (Perform Aseptically):

- Draw 8 milliliters of sterile water into a sterile syringe and needle.
- Apply the supplied vented administration clave to the **PrecisePRP™ Canine** vial and firmly seat it on the crimped seal.
- Disengage the needle and, using sterile technique, attach the syringe to the clave hub.
- Slowly add the sterile water down the side of the vial lumen to avoid foaming and immerse the cake in the rehydrating fluid.
- Gently mix the fluid and the lyophilized powder by swirling the vial to rehydrate.
- Draw into a syringe using the bidirectional clave.
- Engage a needle greater than or equal to 22 gauge for administration.
- Store at room temperature (18-25°C) until administration for not more than four (4) hours.
- Discard the excess product.

Dosage:
Dosage is lesion dependent and determined by the practitioner at the time of use. Each microliter of **PrecisePRP™ Canine** contains 500,000 +/- 100,000 platelets and less than 1500 white blood cells. The dose given may be adjusted based on the size of the dog and the joint being injected. The following table is a general guide to dosing based upon literature references.

Table 1. Canine Joint Dosing Chart

Joint	Small Dog 1-20 kg	Large Dog >20 kg
Small Joint (i.e., tarsus, carpus)	0.5 mL	2.0 mL
Large Joint (i.e., stifle, hip)	1.0 mL	2.0 mL

CONTRAINDICATIONS:

Do not use in dogs with known hypersensitivity to **PrecisePRP™ Canine**.

WARNINGS:

For use in dogs only. Not for use in humans. Keep out of reach of children. Rehydrated **PrecisePRP™ Canine** should be used within 4 hours of rehydration.

PRECAUTIONS:

PrecisePRP™ Canine has only been tested in mature adult dogs.

PrecisePRP™ Canine has not been evaluated in breeding, pregnant, or lactating dogs.

PrecisePRP™ Canine is not intended for intravenous administration.

ADVERSE REACTIONS:

PrecisePRP™ Canine is made using platelets and plasma from up to 32 canine donors and, as with all blood products, has a risk of infectious disease. Donor maintenance includes routine screening for pathogens by PCR and ELISA testing.

In a randomized, placebo-controlled study of 12 laboratory beagles, **PrecisePRP™ Canine** was tested at the label dose of 2 mL per joint in two consecutive joint injections two weeks apart. There were no adverse treatment-related effects on body weights, gait, daily health observations, temperature, pulse, respiration, clinical pathology, injection sites, no significant findings on veterinary physical exams, and no adverse events as a result of treatment.

Published safety data exists for both canine and equine allogeneic platelet-rich plasma. Clinical case reports, systemic literature reviews, preclinical safety analysis, and comparative studies with autologous platelet-rich plasma and mesenchymal stem cells are available for the horse and dog. In the safety evaluation published by Garbin[1], a pooled allogeneic freeze-dried PRP was evaluated with autologous frozen products for safety and found to be statistically unremarkable from autologous products relating to inflammation and lameness post injection. In an Italian clinical trial in canine patients, no adverse events associated with immunogenicity were noted utilizing a pooled allogeneic platelet-rich plasma[2].

Report any suspected adverse reactions associated with the use of **PrecisePRP™ Canine** to VetStem Customer Service by calling 858-748-2004. For additional information about adverse drug experience reporting animal drugs, contact FDA at 1-888-FDA-VETS or visit www.fda.gov/animalveterinary/safetyhealth.

INFORMATION FOR DOG OWNERS:

Owners of patients should be made aware of the use of allogeneic blood products and their possible side effects. Adverse reactions may include joint pain for several days following injection, transient inflammation and swelling in the injected joint, joint infections, and transmission of disease agents from donor animals.

CLINICAL PHARMACOLOGY:

Platelet-rich plasma has been studied in multiple species with varying use profiles. A thorough review of the literature yielded over 30 references in support of platelet-rich plasma and its use as a topical, intra-articular and/or intralesional therapy published since 2008. Meta-analysis in human clinical trials as well as multiple study reviews in canine and equine suggest that the most common concern for platelet-rich plasma effectiveness is associated with a lack of uniformity and standardization[3, 4]. Important components of platelet-rich plasma have been debated; however, total platelet dose, growth factor content, and leucocyte count appear to be common factors for most authors when relating in vitro characterization and effectiveness outcomes[5]. Review of the veterinary literature was used to support both potential indications as well as dose and administration.

Platelets are provided to supply the growth factors and cytokines located in the alpha granules. After administration, the growth factors and cytokines are released into the area of injection and provide anti-inflammatory cytokines and repair signaling. Platelets also release factors that attract mesenchymal stem cells, leucocytes, and other mononuclear immune cells to assist in the repair process. It has been reported that PRP injected reduces pain signaling.

Recently, the discussion of platelet phenotypes and their relationships to platelet function, circulation, and membrane characteristic have led to the exploration of new methods for platelet concentrate storage, including storage at 4-8°C. Current published uses of platelet-rich plasma in the canine and equine support that it can be used intra-articularly, intralesionally, or topically and should be activated to allow the release of dense and alpha granules. Cold-stored platelets have been characterized as moderately activated as compared to room temperature-stored platelets. Recent in vitro characterization of the cold-stored platelets supports that their phenotype is most consistent with the desired function of platelet-rich plasma[6]. Manipulating the storage parameter for platelet concentrates prior to pooling and lyophilization allows platelet lyophilization without cryopreservatives (VetStem pilot data, 2022).

SAFETY:

PrecisePRP™ Canine was studied in a randomized, masked, placebo-controlled target animal safety study of 12 (adult beagles) at the label dose of 2 mL in comparison to a blinded control group injected with 2 mL of placebo saline. The dogs were injected in one stifle joint and one hip joint, with the injections being two weeks apart. Dogs were followed for seven days after each injection and monitored for clinical and laboratory safety of the **PrecisePRP™ Canine** injections. This study was conducted with a formal IACUC approval and was conducted at an independent testing facility.

There were no adverse treatment-related effects on body weights, gait, daily health observations, temperature, pulse, respiration, clinical pathology, injection sites, no significant findings on veterinary physical exams, and no adverse events as a result of treatment. Specific evaluations of the injected joints included heat, joint swelling, and passive flexion pain as well as lameness evaluation.

STORAGE CONDITIONS:

Store the lyophilized **PrecisePRP™ Canine** at room temperature (18-25°C). Current expiration dating is two years from manufacturing date. Use the rehydrated **PrecisePRP™ Canine** within 4 hours of rehydration.

HOW SUPPLIED:

PrecisePRP™ Canine is supplied as a freeze-dried product in a 50 mL vial. Each vial contains approximately 4 x 10^9 canine platelets at a concentration of 500,000 +/- 100,000 platelets per µL and less than 1500 white blood cells per µL.

Manufactured By:

VetStem, Inc
Poway, CA 92064 USA
1-858-748-2004

REFERENCES:

1. Garbin, L.C., et al., *A safety evaluation of allogeneic freeze-dried platelet-rich plasma or conditioned serum compared to autologous frozen products equivalents in equine healthy joints.* BMC Vet Res, 2022. **18**(1): p. 141.
2. Catarino, J., et al., *Treatment of canine osteoarthritis with allogeneic platelet-rich plasma: review of five cases.* Open Vet J, 2020. **10**(2): p. 226-231.
3. Everts, P.A., et al., *Modifying Orthobiological PRP Therapies Are Imperative for the Advancement of Treatment Outcomes in Musculoskeletal Pathologies.* Biomedicines, 2022. **10**(11).
4. Garbin LC, et al., (2021), *A Critical Overview of the Use of Platelet-Rich Plasma in Equine Medicine Over the Last Decade*. Front. Vet. Sci. 8:641818.
5. McCarrel, T. and L. Fortier, *Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression.* J Orthop Res, 2009. **27**(8): p. 1033-42.
6. Zhao, H.Q., et al., *Cold-stored platelets are effective in an in vitro model of massive transfusion protocol assessed by rotational thromboelastometry.* Transfusion, 2022. **62 Suppl 1**: p. S53-S62.

FDA VMF 006-550Patent Pending

Revised 30Jan2024
6135-0001-002-4444